Edwards Lifesciences Corp. (NYSE:EW) estimates and price target were increased by Jefferies after its physician surveys on transcatheter aortic valve replacement suggested strong procedure growth. The firm maintains its Buy rating on the stock.
Cepheid (NASDAQ:CPHD) expansion plan is viewed by UBS as being the correct move, and the firm states that it would use weakness as a buying opportunity. Shares have a Buy rating and a $43 price target.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
International Business Machines Corp. (NYSE:IBM): Accenture (NYSE:ACN) reported stronger results and guidance than predicted, causing RBC Capital to believe that IBM (NYSE:IBM) will report upbeat signings results. The firm thinks that IBM’s signings will see a rise during 2H12, but it keeps its Sector Perform rating on the stock.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) target has been increased by JMP Securities since the firm continues to be impressed by the initial proof of concept data for ACH-3102. The firm views Achillion as possibly becoming a major competitor in the HCV genotype-1 sector, and it keeps its Outperform rating on the stock.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) along with Astellas Pharma a submission by AVEO of a New Drug Application to the U.S. Food and Drug Administration, as it attempts to gain approval for tivozanib in patients dealing with advanced renal cell carcinoma. Tivozanib should target the vascular endothelial growth factor pathway, which is a clinically validated target in RCC and other solid tumors. The NDA submission is based on results of the global Phase 3 TIVO-1 trial, which is a randomized superiority-designed pivotal trial intended to study the efficacy and safety of tivozanib versus sorafenib in 517 patients with advanced RCC who had no previous treatment with a systemic therapy, along with data from 17 clinical studies that involve over 1,000 subjects who received tivozanib. In TIVO-1, tivozanib showed statistically significant improvements in progression-free survival versus sorafenib, an approved targeted agent, and a favorable tolerability profile.
Don’t Miss: RIM’s Shocker Sends Shares Soaring.